© 2026 Forbes Media LLC. All Rights Reserved.
A multicenter phase II study of first-line modified FOLFIRINOX in patients with advanced urachal cancer (ULTIMA; KCSG GU20-03). The impact of neoadjuvant chemotherapy relative dose intensity on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results